CNS Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	7.2	6.46	0.55	10.06	5
Cash & Short-Term Investments	7.2	6.46	0.55	10.06	5
Cash Growth	11.45%	1077.53%	-94.54%	100.93%	-64.35%
Other Receivables	-	0.88	-	-	-
Total Trade Receivables	-	0.88	-	-	-
Other Current Assets	0.9	1.31	1.04	2.51	2.47
Total Current Assets	8.1	8.66	1.59	12.56	7.48
Net Property, Plant & Equipment	0.02	0.01	0	0.01	0.02
Other Long-Term Assets	0.5	0.04	0.1	0.48	1.26
Total Assets	8.62	8.7	1.7	13.05	8.76
Accounts Payable	3.77	2.2	5.83	4.51	1.98
Accrued Expenses	-	-	-	-	0.22
Short-Term Debt	0.33	0.33	0.3	0.41	0.39
Total Current Liabilities	4.1	2.52	6.13	4.92	2.59
Total Liabilities	4.1	2.52	6.13	4.92	2.59
Common Stock	-	-	0	0	0
Additional Paid-in Capital	-	-	65.13	58.85	41.6
Retained Earnings	-100.28	-84.42	-69.57	-50.72	-35.44
Shareholders' Equity	-100.28	-84.42	-4.43	8.13	6.16
Total Liabilities & Equity	8.62	8.7	1.7	13.05	8.76
Total Debt	0.33	0.33	0.3	0.41	0.39
Net Cash (Debt)	6.87	6.14	0.25	9.65	4.62
Net Cash Growth	12.02%	2374.76%	-97.43%	108.92%	-66.05%
Net Cash Per Share	15.50	192.79	1974.11	76805.09	157667.25
Book Value	-100.28	-84.42	-4.43	8.13	6.16
Book Value Per Share	-226.17	-2652.95	-35292.22	64760.63	210481.40
Tangible Book Value	-100.28	-84.42	-4.43	8.13	6.16
Tangible Book Value Per Share	-226.17	-2652.95	-35292.22	64760.63	210481.40

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q